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Poster Session II 143numbers at any time point, did not correlate with any of the analysed
factors. Lower numbers of mDC and pDC in the PB at 3 months
after transplant significantly correlated with increased overall and
transplant-related mortality in univariate analysis. In multivariate
analysis low mDC counts correlated with increased overall mortal-
ity (p 5 0.008) whereas low pDC counts correlated with increased
TRM (p 5 0.07). PB Monocyte numbers instead did not correlate
with any of the analysed end points. Conclusion: Recovery of
mDC and pDC 3–12 months after transplant was reduced in pa-
tients with advanced disease at transplant, or developing acute or
chronic extensive GVHD after transplant. Nevertheless, a delayed
recovery of mDC and pDC within 3 months after transplant was
an independent factor contributing to a greater mortality.393
PRESENCE OF ACTIVATING KIR GENOTYPES INFLUENCES CYTOMEGA-
LOVIRUS (CMV) REACTIVATION AS DETECTED BY Q-PCR IN HCT RECIP-
IENTS
Sun, J.1, Gallez-Hawkins, G.M.2, Thao, L.2, Li, X.2, Franck, A.E.2,
Dagis, A.3, Senitzer, D.1, Forman, S.J.1, Zaia, J.A.2. 1City of Hope,
Duarte, CA; 2Beckman Research Institute of City of Hope, Duarte,
CA; 3City of Hope, Duarte, CA.
Killer Ig-like receptor (KIR) is a cluster of natural killer cell re-
ceptors presented by T cells and natural killer (NK) cells. The com-
patibility of these receptors between the donor and the recipient
plays a role in hematopoietic cell transplantation (HCT) for either
activating (aKIR) or inhibitory KIRs. Some aKIRs bind only weakly
to HLA class I and the natural ligands remain undetermined
whereas the inhibitory KIRs bind HLA class I molecules with spec-
ificity for defined alleles of HLA-C, HLA-B, or HLA-A. It has been
suggested that the donor KIR genotype influences the rate of CMV
infection and, more particularly, that aKIR genes are inversely asso-
ciated with CMV reactivation (Cook et al Blood 2006; 107: 1230–
32; Chen et al. BMT 2006; 38: 437–44). In this study, a cohort of
92 non T-cell depleted subjects, who had received a matched unre-
lated or HLA identical related donor, were analyzed for inhibitory
KIR ligands and KIR genotypes obtained using a multiplex PCR-
SSPmethod. All recipients were at risk for CMV reactivation which
was monitored bi-weekly by Q-PCR on plasma DNA.
Results: Two groups, those with CMV reactivation (n 5 68) vs
No CMV (n 5 24), were compared for the presence of KIR deter-
minants and analyzed using a contingency table with Chi2 test for
probability values. An increased number of aKIR genes in the do-
nor, either involving an A haplotype, carrying a single aKIR gene,
or the AB and BB haplotypes carrying more than one aKIRs, was
significantly associated with a reduction of CMV reactivation (p
5 0.0438). In addition, using a previously described algorithm for
scoring KIR determinants in donor and recipient (Sun et al. BMT
2005; 56: 525–530), values .0, associated with more aKIRs in the
donor but not in the recipient, were associated with significantly
less CMV reactivation (62%VS 85%, p5 0.0372).When the recip-
ients were analyzed for HLA-CwKIR ligand group1 or 2, there was
no significant association with CMV reactivation. This was still true
whenHLA class I mismatched donor-recipient pairs were excluded.
Conclusion: In theHCT setting, aKIR genes in donor cells protect
the recipient from CMV reactivation but the HLA-Cw allotype of
the recipient does not predict CMV infection.394
VACCINATION WITH CARNARYPOX PP65 CMV VACCINE INDUCES RELI-
ABLE CD41 AND CD81 T CELL RESPONSES ONLY IN INDIVIDUALS
WHO LACK BASELINE RESPONSES. IMPLICATIONS FOR DONOR VACCI-
NATION TO BOOST CMV IMMUNITY IN STEM CELL TRANSPLANT RECIP-
IENTS
Shenoy, A.1, Solomon, S.2, Pichon, S.3, Cadoz, M.3, Barrett, A.J.1.
1NIH, Bethesda, MD; 2The Blood and Marrow Transplant Program,
Atlanta, GA; 3Sanofi Pasteur, Marcy L’etoile, France.CMV reactivation after allogeniec stem cell transplant (SCT) re-
mains a major cause of post-transplant morbidity but may be miti-
gated by strong T-cell responses in the transplanted donor T-cell
repertoire.We vaccinated 25 subjects with ‘‘ALVAC pp-65’’ (sanofi
pasteur, Lyon, France) to boost CMV responses in seropositive sub-
jects and induce CMV responses in seronegative subjects. An accel-
erated regimen giving 1.0 ml ALVAC pp-65 on days 0 and 5 to
seropositive subjects and days 0, 5, and 10 to seronegative individ-
uals was used. CD41 and CD81 T-cell responses to a CMV
pp65 peptide library were measured at serial timepoints post vacci-
nation using flow cytometry to identify interferon-gamma produc-
ing T-cells. Positive responses were defined as a twofold increase of
interferon-gamma production compared to unstimulated cells. Of
the 25 subjects analyzed, 13 were seropositive and 12 were seroneg-
ative. As previously reported, serostatus did not correlate with base-
line CD41 and CD81 CMV response. Indeed there were no
differences in T-cell response patterns according to serostatus.
We therefore segregated subjects into baseline CD41 or CD81 re-
sponders or non-responders irrespective of serostatus. Six of 9
CD41 non-responders had a 2–8 fold (median 4) increase in re-
sponse by day 5. In contrast, 13 of 16 subjects with a baseline
CD4 response (identified by a stimulation index of $2 at baseline)
showed decreased or undetectable responses at day 5 with variable
responses thereafter. Nine of 11 CD81 non-responders had a 2–9
fold (median 3) response by day 5. In contrast, 10 of 14 CD81 re-
sponders showed decreased response by day 5 with variable re-
sponses thereafter. Apart from pain at the injection site, vaccine
was well tolerated. These results show that ALVAC is a well toler-
ated vaccine with the potential to induce pp65 responses in subjects
who lack baseline responses. In subjects that have baseline re-
sponses, vaccination appears to dampen immediate immune re-
sponse. It is unclear if the vaccine is inducing tolerance in these
individuals and if this is related to dose of the vaccine. ALVAC
pp65 can elicit quick responses of varying duration in subjects
that lack CD4 or CD81T cell responses to CMV and could there-
fore be used to improve the transfer of CMV immunity to SCT re-
cipients using such donors. However, in donors that have a baseline
CMV response, vaccination may be detrimental to the recipients’
ability to respond to CMV.395
IMPACT OF DONOR T CELLS ON B CELL DEVELOPMENT AFTER HEMA-
TOPOIETIC CELL TRANSPLANTATION: LESSONS FROM B CELL DEFI-
CIENT MICE
Mueller, A.M.S.1,2, Allen, J.A.1, Miklos, D.1, Tung, J.W.3,
Shizuru, J.A.1. 1Stanford School of Medicine, Stanford, CA; 2University
Medical Center, Freiburg i.Br., Germany; 3Stanford School of Medicine,
Stanford, CA.
Allogeneic hematopoietic cell transplant (HCT) recipients often
exhibit B cell (BC) lymphopenia due, in part, to graft-versus-host-
disease (GVHD). Here, we studied the influence of donor T cells
(TC) on BC deficiency post-HCT. Following lethal irradiation,
BALB. B mice were given FACS purified hematopoietic stem cells
(HSC: cKIT1Thy1.1loLin-Sca-11) alone, or with co-transfer of
whole splenocytes (SP), CD4 or CD8 TCs from minor antigen-
mismatched C57BL/6 (B6) mice. When pure HSC were trans-
planted, BC reconstituted promptly (median 33% of lymphocytes
[d30]; 61% [d60]; 74% [d90]), whereas TC engraftment was re-
tarded and did not achieve full donor chimerism. In contrast, addi-
tion of SP or CD4 TCs substantially suppressed BC reconstitution,
correlating with the degree of acute GVHD, and TC transfer ad-
vanced TC engraftment and resulted in early conversion to full do-
nor chimerism. To test if previous events in the donor sensitize TCs
against BC structures, thereby promoting anti-BC cytotoxicity
post-HCT, TCs from B cell deficient mMTB6 mice were co-trans-
planted with wild type (WT) HSC. Remarkably, BC engraftment
was completely prevented through d90. TCs regenerated faster,
but the vast majority originated from spleen and not HSC. To dif-
ferentiate this lack of BC engraftment from GVHD-associated al-
loreactive BC lymphopenia, syngenic B6 recipients were used.
Again, initially complete blockade of BC engraftment was observed,
although this suppression was overcome earlier post-HCT as
144 Poster Session IIcompared to the minor-mismatched pair. Conversely, when WT
HSC and TCs were transplanted into myeloablated and non-mye-
loablated mMTmice, BC engraftment was readily established, mak-
ing a direct anti-BC cytotoxicity unlikely as the sole cause of the BC
inhibition. FACS analysis of the bone marrow revealed a shift of the
developmental BC stages of from mature to immature stages in B
lymphopenic mice. While GVHD affected mice that received
WT grafts displayed a lower proportion of IgM expressing BCs, re-
cipients of mMTTCs showed a complete block in BC development
with an absent switch to the expression of IgM. In conclusion, TCs
from mMT mice can block BC maturation when transferred into
WTmice, an observation which shows that mature TC are capable
of interfering with BC regeneration post transplantation. This
HCT model using WT and mMT B6 mice provides a powerful
tool for studying the role of TC function in the process of donor
BC development post-HCT.396
B LYMPHOCYTE RECONSTITUTION FOLLOWING ALLOGENEIC STEM
CELL TRANSPLANTATION FOR HAEMATOLOGICAL DISORDERS: CORRE-
LATION WITH PRE- AND POST-TRANSPLANT FACTORS
Richardson, D.S., Hodges, E., Mani, A., Hurlock, C., Newman, J.,
McKeag, N., Hill, K., Orchard, K.H. Southampton University Hospitals,
Southampton, Hampshire, United Kingdom.
We have performed a detailed analysis of the kinetics of B cell re-
constitution in patients who have undergone allogeneic stem cell
transplantation for haematological disorders. Whole blood samples
from 76 patients were analysed using monoclonal antibodies di-
rected against CD19, CD27 and IgD by multicolour flow cytome-
try. Total (CD191), naive (IgD1CD27-), IgD memory
(IgD1CD271) and class switched memory (IgD-CD271) B cell
populations were identified. Indications for transplantation were
haematological malignancy (n 5 74) and aplastic anaemia (n 5 2).
The stem cell source was from an unrelated donor in 29 cases or re-
lated/sibling donor in 47 cases. 39 patients received reduced inten-
sity and 37 full intensity transplant conditioning regimens. In vivo
T-cell depletion with Campath 1H was used for all patients with
a matched unrelated donor and those receiving reduced intensity
conditioning. The majority of patients (n5 57) have retained a pre-
dominantly naive B cell phenotype at 2 to 48 months (median 18.7
months). 7 patients have a normal percentage of memory B lympho-
cytes with a low percentage of class-switched B cells. 7 patients cur-
rently have a normal percentage of class-switched B cells. 8 patients
achieved normal class-switched B cell numbers but returned to a na-
ive B cell phenotype. In one patient this preceded relapse of under-
lying leukaemia and in two others was consequent on treatment
with chemotherapy or corticosteroid. Only one patient who re-
quired treatment with additional immunosuppressive therapy,
post transplant, subsequently achieved a normal percentage of
class-switched B cells. The use of Campath 1H, stem cell source
(marrow or peripheral blood), donor type (unrelated or related),
use of full or reduced intensity conditioning or the administration
of donor lymphocyte infusions post-transplant were not predictive
of development of a normal percentage of class-switched B lympho-
cytes. B cell immune reconstitution phenotype does not appear to
correlate with the incidence of chronic GvHD or in this cohort of
patients with current disease status. The timing of development of
a normal percentage of class-switched B cells cannot be reliably pre-
dicted in this patient population.397
MINIMAL RESIDUAL DISEASE AND CHIMERISM IN CML PATIENTS RE-
CEIVING ALLOGENEIC TRANSPLANTS AFTER MYELOABLATIVE OR RE-
DUCED CONDITIONING
Uzunel, M., Mattsson, J., Hauzenberger, D., Ringden, O. Karolinska
University Hospital, Stockholm, Sweden.
It is not known whether reduced conditioning is associated with
prolonged period of detectable disease after SCT in patients withCML. We have therefore compared BCR-ABL transcript levels in
patients receiving a conventional myeloablative conditioning with
those receiving reduced conditioning. We also made chimerism
studies in both patient groups.
Myeloablative Conditioning (MYC): 31 patients, 19 matched
unrelated donors (MUD) and 12 sibling donors (Sib). Median age
was 42 years (10–61). Conditioning with Bu1Cy (n 5 31). Twenty
of theMUDpatients were also given ATG. Seven patients have died
(6 GVHD, 1 Relapse). Median follow-up time: 56 months (10–99).
Reduced Intensity Conditioning (RIC): 24 patients, 13 MUD
and 11 Sib. Median age was 55 years (11–64). Conditioning with
Flu1Bu1ATG. Seven patients have died (3 Relapses, 1 GVHD,
3 other reasons). Median follow-up time: 43 months (18–100). Re-
sults: There was no statistical significant difference in overall sur-
vival and relapse free survival between both groups. 5/29 patients
in the MYC group relapsed as compared to 7/23 patients in the
RIC group. Only one patient in the RIC group rejected the graft.
The incidence of severe acute GVHD was significantly higher in
the MYC group (48%) as compared to the RIC group (13%), p 5
0.004. Interestingly, the incidence of chronic GVHD was slightly
higher in the RIC group, 51% vs. 37% (p 5 0.11).
During the first 3 months, MRD levels in the RIC group was in
median one log of magnitude higher than in the MYC group (p 5
0.01). After that, no significant differences in the MRD incidence
and MRD level were found between the groups.
Median time to complete donor T-cell chimerism was 34 days
(14–285) in the MYC group as compared to 60 days (24–245) in
the RIC group (p5 0.04). Also, complete myeloid cell engraftment
was delayed in the RIC group, median 44 days (14–165) as
compared to 25 days (14–270) in the MYC group (p 5 0.02).
Conclusion: Despite higher BCR-ABL levels during the early
post-transplant period and higher incidence of mixed chimerism,
nonmyeloablative transplantation for CML patients may induce
molecular remission in the majority of the patients.398
TRANSCRIPTIONAL ANALYSIS OF CD41 T CELLS FROM TOLERANT PA-
TIENTS AND NORMAL CONTROLS. GENE EXPRESSION IN PATIENTS DIF-
FERS FROM NORMAL CONTROLS
Tabellini, L., Haeusermann, P., Bumgarner, T.E., Flowers, M.E.,
Grogan, B.M., Martin, P.J., Hansen, J.A. Fred Hutchinson Cancer Re-
search Center, Seattle, WA.
GVHD is a major complication of hematopoietic cells transplan-
tation (HCT). Immune suppression therapy (IST) is administered
for prophylaxis and treatment of GVHD. Chronic GVHD usually
occurs within 3 to 24 months from HCT, and requires on average
24 months of IST before disease becomes quiescent and IST can
be withdrawn. We have characterized gene expression changes in
CD41 T cells of HCT patients with resolved GVHD to see if dis-
tinct translational changes are associated with immunological toler-
ance. The study included 10 patients who had been off all IST for at
least 4 months (median 9 months; range 4–38 months) without ev-
idence of active cGVHD. Six achieved tolerance within the first year
(‘‘early’’ tolerance). Four developed cGVHD within the first year
but were subsequently withdrawn from all IST between 6–38
months post-HCT (‘‘late’’ tolerance). Blood samples from early tol-
erants were obtained between 12–29 (median 12) months, from the
late tolerants were obtained between 38–52 (median 45) months
post-HCT. CD41 T cells were isolated from cryopreserved
PBMC. RNA was hybridized on HumanRef-8 v2 BeadChips,
scanned and normalized using BeadStudio (Illumina), gene expres-
sion in CD41T cells from the 10 tolerant patients was compared to
gene expression in CD41 T cells from 19 normal controls using
a false positive discovery rate of \10. Expression levels differed
for 266 genes in tolerant patients (124 upregulated and 142 down-
regulated) compared to normal controls; and 189 of these genes
could be assigned to a functional class. Selected examples are:
DNA repair (6 genes); cell cycle regulation (18 genes); RNA tran-
scription (9 genes); protein translation (8 genes); ubiquitin cycle
(6 genes); glycolysis and aerobic respiration pathways (5 genes);
and lipid metabolism (3 genes). FAS gene showed relatively strong
upregulation in all patients. Although the numbers of early and late
